Skip to content
Avalide, Aprovel(irbesartan)
Aprovel, Avalide, Avapro, CoAprovel, Karvea, Karvezide (irbesartan) is a small molecule pharmaceutical. Irbesartan was first approved as Aprovel on 1997-08-26. It is used to treat diabetic nephropathies, hypertension, and left ventricular dysfunction in the USA. It has been approved in Europe to treat hypertension. It is known to target type-1 angiotensin II receptor and hepatic sodium/bile acid cotransporter.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Avapro (generic drugs available since 2012-03-30)
Combinations
Avalide (generic drugs available since 2012-03-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrochlorothiazide
+
Irbesartan
Tradename
Company
Number
Date
Products
AVALIDESanofiN-020758 RX1997-09-30
2 products, RLD, RS
Show 1 discontinued
Irbesartan
Tradename
Company
Number
Date
Products
AVAPROSanofiN-020757 RX1997-09-30
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
avalideNew Drug Application2021-11-16
avaproNew Drug Application2021-01-12
irbesartan and hydrochlorothiazideANDA2023-05-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic nephropathiesEFO_0000401D003928—
hypertensionEFO_0000537D006973I10
left ventricular dysfunction—D018487—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA04: Irbesartan
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA04: Irbesartan and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB05: Irbesartan and amlodipine
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
— C09DX07: Irbesartan, amlodipine and hydrochlorothiazide
HCPCS
No data
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10141322544
Healthy volunteers/patients—5——139
Type 2 diabetes mellitusD003924EFO_0001360E11——14—5
Diabetic nephropathiesD003928EFO_00004011112—4
Atrial fibrillationD001281EFO_0000275I48.0——31—4
ObesityD009765EFO_0001073E66.9—1—113
Heart failureD006333EFO_0003144I50——12—3
Metabolic syndromeD024821EFO_0000195E88.81———112
Abdominal obesityD056128HP_0001956———1—1
Renin-angiotensin systemD012084———1—1
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Essential hypertensionD000075222I10—12——3
Chronic renal insufficiencyD051436N18—11—13
Iga glomerulonephritisD005922EFO_0004194——2——2
Focal segmental glomerulosclerosisD005923EFO_0004236—11——2
Chronic kidney failureD007676EFO_0003884N18.6——2——2
Covid-19D000086382U07.1——1——1
Ehlers-danlos syndromeD004535Orphanet_98249Q79.6——1——1
SepsisD018805A41.9——1——1
HyperlipidemiasD006949EFO_0003774E78.5——1——1
Kidney transplantationD016030——1——1
Show 9 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Blood pressureD001794EFO_0004325—1———1
Psychological stressD013315—1———1
Ebola hemorrhagic feverD019142EFO_0007243A98.411———1
Marfan syndromeD008382Orphanet_558Q87.4—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Therapeutic equivalencyD0138101————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Morbid obesityD009767EFO_0001074————11
Pregnancy-induced hypertensionD046110O13————11
Pre-eclampsiaD011225EFO_0000668O14————11
Insulin resistanceD007333EFO_0002614————11
MicrocirculationD008833————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIRBESARTAN
INNirbesartan
Description
Irbesartan is a biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an environmental contaminant and a xenobiotic. It is a biphenylyltetrazole and an azaspiro compound.
Classification
Small molecule
Drug classangiotensin II receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Identifiers
PDB—
CAS-ID138402-11-6
RxCUI83818
ChEMBL IDCHEMBL1513
ChEBI ID5959
PubChem CID3749
DrugBankDB01029
UNII IDJ0E2756Z7N (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AGTR1
AGTR1
SLC10A1
SLC10A1
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,231 documents
View more details
Safety
Black-box Warning
Black-box warning for: Avalide, Avapro, Irbesartan and hydrochlorothiazide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
30,289 adverse events reported
View more details